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1 Both contribute equally to this work.Swati Shukla a,1; Manzoor Ahmad Malik a,1; Parijat Chandra b; Jasbir Kaur a,⇑AbstractPurpose: Vascular endothelial growth factor (VEGF) contributes to the development of retinopathy of prematurity (ROP). A num-
ber of studies investigated the association of ROP with VEGF 460 T/C and +936 C/T polymorphisms but the results were
conflicting. In order to derive a more precise estimation of the associations, we performed a meta-analysis of the relationship
between VEGF 460 T/C and +936 C/T polymorphisms with ROP in all published studies.
Methods: A literature search was performed systematically using electronic databases. Published literature from PubMed and
other databases was retrieved. The odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Each
460 T/C and +936 C/T polymorphism included four case-control studies including case/control 249/308 and 179/250
respectively.
Results: Through literature search, we found that both VEGF 460 T/C and +936 C/T polymorphisms were not associated with
ROP risk at allelic, co-dominant, dominant and recessive models.
Conclusions: This meta-analysis suggests that the VEGF 460 T/C and +936 C/T polymorphism might contribute to genetic sus-
ceptibility of ROP. The association between VEGF 460 T/C and +936 C/T polymorphism and ROP risk awaits further
investigation.
Keywords: VEGF, ROP, Polymorphism, Meta-analysis
 2016 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Retinopathy of prematurity (ROP) is a disorder in which
retinal blood vessels fail to develop normally, sometimes
resulting in visual impairment and blindness in premature
infants. In the early stages of retinal vascular development,
premature neonates are exposed to higher oxygen levels
eliminating physiological hypoxia, thus down-regulating
angiogenic factors that are required for the growth of thevasculature. ROP occurs in premature infants with disruption
of this angiogenic phase. Vascular endothelial growth factor
(VEGF) plays an important role in both physiological and
pathologic angiogenesis. Discovery of growth factors acting
on the vascular endothelium has coincided with application
of powerful new genetic approaches to the problem of vascu-
lar development. A number of studies have investigated and
observed that VEGF messenger ribonucleic acid (mRNA)
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ROP.1,2
The human VEGF gene (OMIM 192240) is located on chro-
mosome 6p12. Many polymorphisms of the VEGF gene have
been reported, although most are relatively rare. Single
nucleotide polymorphisms (SNPs) in the VEGF 460 T/C
(rs833061) and +936 C/T (rs3025039) in the respective 50
and 30 untranslated region (UTR) have been reported in dif-
ferent populations.3 Some studies have found association of
VEGF 460 T/C or +936 C/T polymorphism with ROP
risk,4–6 but some other studies show no association between
VEGF 460 T/C or +936 C/T polymorphism and risk of
ROP.7–11 These studies revealed a conflicting conclusion,
probably due to the relatively small size of subjects, since
individual studies are usually underpowered in detecting
the effect of low penetrance genes. Therefore, in this study
we conducted a meta-analysis to investigate the association
between VEGF 460 T/C and +936 C/T polymorphism and
the risk for ROP.Materials and methods
Identification and eligibility of relevant studies
To identify all articles that examined the association of
VEGF 460 T/C and +936 C/T polymorphism with ROP, we
conducted a literature search in the PubMed, EMBASE,
Cochrane Library, Google, dogpile and CBM database, up
to July 2015 using the following terms and keywords: ‘‘VEG
F’’, ‘‘vascular endothelial growth factor’’, ‘‘460 T/C’’
‘‘rs833061’’ ‘‘+936 C/T’’ ‘‘rs3025039’’ polymorphism’’ and
‘‘retinopathy of prematurity’’. Additional studies were identi-
fied by a manual search from other sources (e.g., Web of
Knowledge), references of original studies or review articles
on this topic.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) studies are lim-
ited to VEGF 460 T/C and +936 C/T polymorphism and
ROP; (2) Independent case-control studies using either a
hospital-based or a population based design; (3) complete
data with genotype and allele frequencies; (4) the literature
having a comprehensive statistical index, sufficient data for
estimating an odds ratio (OR) with 95% confidence interval
(CI); (5) the genotype frequency of cases and controls was
within Hardy-Weinberg equilibrium (HWE); (6) papers pub-
lished in English and (7) all the studies included were accord-
ing to tenets of the Declaration of Helsinki.
The major reasons for exclusion of studies were (1) studies
which were not possible to extract data from the published
results; (2) studies that did not report appropriate outcomes;
(3) Duplicated studies were also excluded; (4) case-only stud-
ies; (5) all three genotype frequency missing and (6) family
based studies.
Data extraction
Authors independently reviewed all the potentially rele-
vant papers through assessing the eligibility of each article
and abstracting data with standardized data-abstraction
forms. For each study, the following information wasextracted: name of the first author; publication year; ethnic-
ity; sample size; types of disease; sources of samples; geno-
typing methods; and the minor allele frequency in the
controls with the Hardy-Weinberg Equilibrium (HWE)
p-value, respectively. Disagreements were resolved through
discussion. The characteristics of these studies included in
this meta-analysis on the association of ROP with VEGF
460 T/C and +936 C/T polymorphism are shown in Tables
1 and 2. The VEGF 460 T/C and +936 C/T polymorphism
genotype distributions from each study is presented in
Tables 3 and 4 respectively.
Statistical analysis
ORs and relevant 95% CIs were computed using review
manager (comprehensive meta-analysis version 3).12 ORs
were used to measure association across the studies. The risk
of VEGF 460 T/C CC genotype on retinopathy of prematu-
rity was evaluated by comparing with their reference wild
type homozygote and then evaluated the risks of TC + CC
vs. TT and TT + TC vs. CC on retinopathy of prematurity,
assuming dominant and recessive effects of the variant C
allele, respectively. And the risk of VEGF + 936 C/T and TT
genotype on retinopathy of prematurity was evaluated by
comparing with their reference wild type homozygote and
then evaluated the risks of CT + TT vs. CC and CC + CT vs.
TT on retinopathy of prematurity, assuming dominant and
recessive effects of the variant T allele, respectively. If moder-
ate or high level heterogeneity exists, a random-effects meta-
analysis was performed, unless using fixed-effects models.
Publication bias was assessed by visually inspecting a funnel
plot. A p value less than 0.05 was considered statistically
significant.13
Results
Association of the VEGF 460 T/C polymorphism with
ROP
This meta-analysis included four eligible studies of the
association of the VEGF 460 T/C polymorphism with ROP.
The genetic models all used fixed-effects models. In the over-
all analysis, no significant associations were found in any of
the comparison models including the allele model: T vs. C
(OR = 0.931, 95% CI = 0.726–1.195, P = 0.576) (Fig. 1), dom-
inant model: TC + CC vs TT (OR = 0.895, 95% CI = 0.629–
1.273, P = 0.536) (Fig. 2), recessive model: TT + TC vs. CC
(OR = 1.048, 95% CI = 0.646–1.699, P = 0.849) (Fig. 3) and
co-dominant model: TT vs. CC (OR = 0.911, 95%
CI = 0.537–1.544, P = 0.729) (Fig. 4).
Association of the VEGF +936 C/T polymorphism with
ROP
A total of four studies were included in this meta-analysis.
No significant associations between the VEGF +936 C/T
polymorphism with ROP were identified in any comparison
models, including the allele model: C vs. T (OR = 0.882,
95% CI = 0.610–1.274, P = 0.502) (Fig. 5), dominant model:
CT + TT vs. CC (OR = 0.866, 95% CI = 0.558–1.344,
P = 0.521) (Fig. 6), recessive model: CC + CT vs. TT
(OR = 1.139, 95% CI = 0.487–2.665, P = 0.764) (Fig. 7) and
Table 1. Characteristics of studies included in the VEGF 460 T/C (rs 833061) meta-analysis.
Study Year Country Ethnicity Genotyping method Sample Case Control p-Value References
Vannay et al. 2005 Hungary Caucasian Real-time PCR Blood 86 115 – PMID: 15635051
Shastry et al. 2007 USA Caucasian PCR-RFLP, Sequencing Blood 61 61 0.892 PMID: 17119993
Kwinta et al. 2008 America Caucasian PCR-RFLP Blood 60 101 0.024 PMID: 18546007
Kaya et al. 2013 Turkey Asian PCR-RFLP Blood 42 31 0.87 PMID: 23094709
Table 2. Characteristics of studies included in the VEGF +936 C/T (rs 3025039) meta-analysis.
Study Year Country Ethnicity Genotyping method Sample Case Control p-Value References
Cooke et al. 2004 United Kingdom Caucasian PCR, SSCP, RFLP Buccal swab 91 97 0.15 PMID: 15161830
Yagi et al. 2011 Japan Asian Taq Man Buccal mucosa 30 34 0.012 –
Kalmeh et al. 2013 Iran Asian PCR-RFLP Blood 15 66 0.65 PMID: 23644986
Gismondi et al. 2013 USA Caucasian PCR Blood 43 53 0.11 PMID: 22227643
Table 3. VEGF 460 T/C (rs833061) polymorphism genotype distribution of each study included in the meta-analysis.
Author/Year Genotype frequency Allele frequency Dominant model Recessive model
Cases Controls Cases Controls Cases Controls Cases Controls
TT TC CC TT TC CC T C T C TT TC + CC TT TC + CC CC TT + TC CC TT + TC
Vannay et al. (2005) 27 47 12 28 61 26 101 71 117 113 27 59 28 87 12 74 26 89
Shastry et al. (2007) 27 27 7 28 26 7 81 41 82 40 27 34 28 33 7 54 7 54
Kwinta et al. (2008) 32 18 10 55 36 10 82 38 146 56 32 28 55 46 10 50 10 91
Kaya et al. (2013) 17 18 7 11 16 4 52 32 38 24 17 25 11 20 7 35 4 27
Table 4. VEGF +936 C/T (rs3025039) polymorphism genotype distribution of each study included in the meta-analysis.
Author/Year Genotype frequency Allele frequency Dominant model Recessive model
Cases Controls Cases Controls Cases Controls Cases Controls
CC CT TT CC CT TT C T C T CC CT + TT CC CT + TT TT CC + CT TT CC + CT
Cooke et al. (2004) 67 19 5 68 21 8 153 29 157 37 67 24 68 29 5 86 8 89
Yagi et al. (2007) 14 14 2 27 7 0 42 18 61 7 14 16 27 7 2 28 0 34
Kalmeh et al. (2013) 12 1 2 43 15 8 25 5 101 31 12 3 43 23 2 13 8 58
Gismondi et al. (2013) 31 11 1 28 23 2 73 13 79 27 31 12 28 25 1 42 2 51
Figure 1. Meta-analysis under allelic model (T vs. C) for the association between ROP risk and the VEGF 460 T/C polymorphism. The squares and
horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond
represents the pooled OR and its 95% CI.
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CI = 0.347–1.931, P = 0.648) (Fig. 8).
Sensitivity analysis and publication bias
Individual studies were consecutively excluded in the sen-
sitivity analysis to investigate whether the obtained resultswere robust. The analysis showed that the results obtained
in the meta-analysis were statistically robust, because the
corresponding combined ORs in all of the separate subgroup
analyses were relatively stable when deleting any individual
study. The influence of CC genotype at 460 T/C locus on
ROP was taken as the analysis index and inverted funnel plot
was drawn (Fig. 9); TT genotype at +936 C/T locus on ROP
Figure 2. Meta-analysis under dominant model (TC + CC vs TT) for the association between DR risk and the VEGF 460 T/C polymorphism.
Figure 3. Meta-analysis under recessive model (TT + TC vs. CC) for the association between ROP risk and the VEGF 460 T/C polymorphism.
Figure 4. Forest plots of the association between VEGF 460 T/C (Co-dominant model; TT vs. CC) polymorphism and ROP risk.
160 S. Shukla et al.was taken as the analysis index and inverted funnel plot was
drawn (Fig. 10). Due to the small amount of the included
research and imperceptible distribution trends, the inverted
funnel plot showed trend symmetry, indicating that the pub-
lication bias was not big.
Discussion
As a major factor in angiogenesis, VEGF has attracted
attention because of its involvement in abnormalities of
vascular development, retinal detachment, and ROP. In the
present study, we systemically reviewed all available
published studies and performed a meta-analysis to explorethe association between the VEGF 460 T/C and +936 C/T
polymorphisms and susceptibility to ROP. Our meta-
analysis showed that VEGF 460 T/C and +936 C/T polymor-
phisms were not associated with ROP risk. The deviation
most likely indicates a genotyping assay problem with an
erroneous gain/loss of homozygous genotypes. The com-
monly used polymerase chain reaction-restriction fragment
length polymorphism analysis for genotyping is reported to
have poor accuracy and reproducibility14 and may underlie
this finding. Conversely, effects of sample selection and
differences in biological and environmental complexity
between samples could also hinder efforts to replicate
association in most of the studies which are statistically
Figure 5. Meta-analysis under allelic model (C vs. T) for the association between ROP risk and the VEGF + 936 C/T polymorphism.
Figure 6. Meta-analysis under dominant model (CT + TT vs CC) for the association between ROP risk and the VEGF +936 C/T polymorphism.
Figure 7. Meta-analysis under recessive model (CC + CT vs. TT) for the association between ROP risk and the VEGF +936 C/T polymorphism.
Figure 8. Forest plots of the association between VEGF +936 C/T (Co-dominant model; CC vs. TT) polymorphism and ROP risk.
Association between VEGF polymorphisms and retinopathy of prematurity risk 161
Figure 9. Funnel plots showed symmetric distribution. Log OR is plotted
against the standard error of log OR for studies on VEGF 460 T/C.
Figure 10. Funnel plots showed symmetric distribution. Log OR is
plotted against the standard error of log OR for studies on VEGF +936
C/T.
162 S. Shukla et al.underpowered. Themeta-analysis helps researchers to deal
with the diversity of the published data but in general cannot
do justice to complex human diseases, which involve multiple
genetic and environmental determinants.15 However, in the
total combined data, no evidence for association between
the VEGF 634 G/C polymorphism genotyped and risk of
ROP was observed. Therefore, the different results across
studies may result from small sample size and/or genotyping
technique rather than ethnic differences. Since the studies
included were very limited, it is necessary to validate the
association between VEGF 634 G/C CC polymorphism
and ROP risk in future studies. A well-designed meta-
analysis can provide valuable information for researchers,
policymakers, and clinicians.
In conclusion, the present meta-analysis suggested that
VEGF 460 T/C and +936 C/T polymorphism may not be
associated with risk for ROP. More epidemiologic studies
are suggested to further ascertain the relationship betweenVEGF 460 T/C and +936 C/T polymorphism and genetic
predisposition to ROP.
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